Go or no go? Bristol’s Tyk2 test
A green light from the FDA is expected for deucravacitinib, while Amylyx, Ferring and Oncopeptides head for panels.
Drug makers leave the pain behind
Developing non-opioid analgesics remains one of the hardest tasks in biopharma.
Pfizer bets $5.4bn against gene therapies in sickle cell
Hopefully the acquisition of Global Blood Therapeutics will go better than Pfizer’s last foray into sickle cell deal-making.
No place for Wee1 in Astra’s synthetic lethality work
Wee1 competitors including Zentalis might look with trepidation on Astra and Roche’s recent moves into ATR inhibition.
Go or no go? J&J’s bispecific FDA first
Pdufa decisions also beckon for Amicus, Acadia and Bluebird.
Few biopharma risers stand out at the half year
A look for winners and losers finds a sector laid low by poor sentiment and Covid fatigue, with Lantheus, Vertex and Jazz providing a few bright spots.
EHA 2022 – Crispr still looks bloody good
Updated data with exa-cel in sickle cell disease and beta-thalassaemia could put the fear into competitors.
